Loading clinical trials...
Loading clinical trials...
The goal of this study is to evaluate antiproliferative effects of Arimidex in ductal lavage fluids of Breast Cancer patients. Breast cancer is the leading cause of cancer incidence and the second leading cause of cancer mortality in women. Breast duct fluid provide biomarkers to aid in risk assessment of developing breast cancer.
Age
All ages
Sex
FEMALE
Healthy Volunteers
No
UT MD Anderson Cancer Center
Houston, Texas, United States
Start Date
November 1, 2002
Primary Completion Date
January 1, 2006
Completion Date
January 1, 2006
Last Updated
July 30, 2012
42
ACTUAL participants
Ductal Lavage Fluid Collection
PROCEDURE
Lead Sponsor
M.D. Anderson Cancer Center
NCT04550494
NCT05372640
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions